Omada Health, Inc. (OMDA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reveals strong financial performance with a 25% revenue growth, improved gross margin, and a 33% increase in net income. Despite a rise in operating expenses, the increase was due to strategic investments. The Q&A section does not provide additional insights or concerns. Overall, these factors suggest a positive sentiment, likely leading to a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue Omada Health reported a revenue of $150 million for Q1 2026, representing a 25% year-over-year increase. This growth was driven by an expansion in customer base and higher adoption of digital health solutions.
Gross Margin The gross margin for Q1 2026 was 65%, up from 60% in Q1 2025. The improvement was attributed to operational efficiencies and cost optimization measures.
Net Income Net income stood at $20 million for Q1 2026, compared to $15 million in Q1 2025, marking a 33% increase. This was due to higher revenue and improved cost management.
Operating Expenses Operating expenses were $80 million in Q1 2026, up from $70 million in Q1 2025, reflecting a 14% increase. The rise was primarily due to investments in R&D and marketing.
Cash Flow from Operations Cash flow from operations was $30 million in Q1 2026, a 20% increase from $25 million in Q1 2025. This was driven by improved collections and operational efficiencies.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
Ayush Vyas
Berenshteyn Wells
Buecker Barclays
Carly Buecker
Chief Accounting
Citizens JMP
Close Canaccord
Constantine Davides
Cook Chief
Davides Citizens
Division Constantine
Division Eugene
Division PM
Division Roman
EDT day
Eugene Mannheimer
Executions Inc
JMP Securities
LLC Research
Mannheimer Prime
Officer Craig
Officer Investor
Officer Sean
Omada Health
PM EDT
Prime Executions
Research Ayush
Securities LLC
Vyas Evercore
day Omada
OMDA Transcript
Omada Health, Inc. (OMDA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary reveals strong financial performance with a 25% revenue growth, improved gross margin, and a 33% increase in net income. Despite a rise in operating expenses, the increase was due to strategic investments. The Q&A section does not provide additional insights or concerns. Overall, these factors suggest a positive sentiment, likely leading to a stock price increase of 2% to 8% over the next two weeks.
Maple Leaf Foods Inc. (MFI:CA) Q4 2025 Earnings Call Transcript
Positive3-6
The earnings call summary indicates strong financial performance with revenue, gross margin, and net income all showing significant year-over-year improvements. The strategic focus on plant-based protein and technology investments suggests positive future growth. Despite the lack of specific shareholder return plans, the overall outlook is optimistic with revenue and margin growth expectations. The absence of negative analyst sentiment in the Q&A further supports a positive sentiment rating.
Omada Health, Inc. (OMDA) Q4 2025 Earnings Call Transcript
Positive3-6
Omada Health demonstrated strong financial performance with a 25% revenue growth, improved gross margins, and increased net income. The guidance for 2025 indicates significant revenue growth and a move towards breakeven, showing optimism. While risks were not explicitly discussed, the strategic investments in AI and GLP-1 prescribing suggest a focus on future growth. The lack of negative sentiment in the Q&A and absence of negative guidance adjustments support a positive outlook. Despite the absence of market cap data, these factors collectively suggest a positive stock price reaction.
Omada Health, Inc. (OMDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
